Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Change in Cash (2016 - 2025)

Historic Change in Cash for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to $3.8 million.

  • Niagen Bioscience's Change in Cash fell 1544.43% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.9 million, marking a year-over-year increase of 46696.89%. This contributed to the annual value of $17.3 million for FY2024, which is 15181.58% up from last year.
  • Latest data reveals that Niagen Bioscience reported Change in Cash of $3.8 million as of Q3 2025, which was down 1544.43% from $4.9 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Change in Cash ranged from a high of $28.0 million in Q1 2021 and a low of -$7.2 million during Q1 2022
  • In the last 5 years, Niagen Bioscience's Change in Cash had a median value of $552000.0 in 2023 and averaged $2.5 million.
  • As far as peak fluctuations go, Niagen Bioscience's Change in Cash tumbled by 50057.42% in 2021, and later surged by 446500.0% in 2025.
  • Niagen Bioscience's Change in Cash (Quarter) stood at -$4.9 million in 2021, then surged by 247.02% to $7.2 million in 2022, then crashed by 92.31% to $552000.0 in 2023, then surged by 2121.38% to $12.3 million in 2024, then crashed by 68.88% to $3.8 million in 2025.
  • Its Change in Cash stands at $3.8 million for Q3 2025, versus $4.9 million for Q2 2025 and $11.0 million for Q1 2025.